Diagens Biotechnology's 2025 Loss Widens

MT Newswires Live
04/30

Hangzhou Diagens Biotechnology (HKG:2526) booked 67.1 million yuan in attributable loss for 2025, widening from a loss of 43.4 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.

The medical imaging products maker's shares gained nearly 3% in afternoon trade Thursday.

Loss per share was 0.84 yuan, compared with 0.55 yuan in 2024.

Revenue more than doubled year on year to 164.4 million yuan from 70.4 million yuan.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10